- Home
- GFI vs RPRX Comparison
GFI vs RPRX Comparison
Compare GFI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFI
- RPRX
- Stock Information
- Founded
- GFI 1887
- RPRX 1996
- Country
- GFI South Africa
- RPRX United States
- Employees
- GFI N/A
- RPRX N/A
- Industry
- GFI Precious Metals
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- GFI Basic Materials
- RPRX Health Care
- Exchange
- GFI Nasdaq
- RPRX Nasdaq
- Market Cap
- GFI 12.4B
- RPRX 11.7B
- IPO Year
- GFI 2007
- RPRX 2020
- Fundamental
- Price
- GFI $13.93
- RPRX $24.83
- Analyst Decision
- GFI Hold
- RPRX Strong Buy
- Analyst Count
- GFI 4
- RPRX 6
- Target Price
- GFI $15.03
- RPRX $41.67
- AVG Volume (30 Days)
- GFI 2.2M
- RPRX 3.1M
- Earning Date
- GFI 12-27-2024
- RPRX 11-06-2024
- Dividend Yield
- GFI 2.79%
- RPRX 3.37%
- EPS Growth
- GFI N/A
- RPRX 518.56
- EPS
- GFI 0.70
- RPRX 2.55
- Revenue
- GFI $4,358,300,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- GFI $18.54
- RPRX $12.21
- Revenue Next Year
- GFI $26.28
- RPRX $11.13
- P/E Ratio
- GFI $19.77
- RPRX $9.84
- Revenue Growth
- GFI 1.30
- RPRX N/A
- 52 Week Low
- GFI $12.19
- RPRX $24.70
- 52 Week High
- GFI $18.97
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- GFI 42.60
- RPRX 34.39
- Support Level
- GFI $13.74
- RPRX $24.70
- Resistance Level
- GFI $15.06
- RPRX $25.28
- Average True Range (ATR)
- GFI 0.33
- RPRX 0.44
- MACD
- GFI 0.02
- RPRX -0.08
- Stochastic Oscillator
- GFI 28.03
- RPRX 20.41
About GFI Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.